PeterJayVan VeldhuizenMD

PubMed

• 1 citations
  Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A.
  Eric A Singer, R Bryan Rumble, Peter J Van Veldhuizen> ;JCO Oncology Practice. 2023 Mar 1
• 8 citations
  Prostate Cancer Stem Cells: The Role of CD133.
  Jianhui Yang, Omar Aljitawi, Peter Van Veldhuizen> ;Cancers. 2022 Nov 5
• Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey.
  Shellie D Ellis, Riha Vaidya, Joseph M Unger, Kelly Stratton, Jessie Gills, Peter Van Veldhuizen, Eileen Mederos, Emily V Dressler, Matthew F Hudson, Charles Kamen, He...> ;Contemporary clinical trials communications. 2022 Oct 1
• 86 citations
  Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
  W Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, Hikmat Al-Ahmadie, Hamid Emamekhoo, Ralph J Hauke, Alexander V Louie, Matthew I Milowsky, Ana M Molina, Trac...> ;Journal of Clinical Oncology. 2022 Sep 1
• 3 citations
  Magmas Inhibition in Prostate Cancer: A Novel Target for Treatment-Resistant Disease.
  Jianhui Yang, Bhaskar C Das, Omar Aljitawi, Avinash Kumar, Sasmita Das, Peter Van Veldhuizen> ;Cancers. 2022 May 31
• 40 citations
  Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
  Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutso...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
• 256 citations
  Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, ...
  Thomas Powles, Tibor Csőszi, Mustafa Ozguroglu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales Barr...> ;The Lancet. Oncology. 2021 Jul 1
• 1 citations
  Surviving Testicular Cancer: The Role of the Contralateral Testicle.
  Anishka D'souza, Peter J. Van Veldhuizen, Chunkit Fung> ;Journal of Clinical Oncology. 2021 Jan 27
• 12 citations
  Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
  Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina, Ralph J Hauke, James A Reeves, Sunil Babu, Peter Van Veldhuizen, Bradley Somer, Vijay ...> ;Clinical Genitourinary Cancer. 2020 Dec 1
• 2 citations
  Circulatory MIC-1 as a Determinant of Prostate Cancer Racial Disparity.
  Dev Karan, Jo Wick, Seema Dubey, Ossama Tawfik, Peter J. Van Veldhuizen> ;Cancers. 2020 Oct 18
• 8 citations
  Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a random...
  Joseph M. Unger, Katherine Griffin, Gary W. Donaldson, Karen Baranowski, Margorie J. Good, Eunicia Reburiano, Maha Hussain, Paul Monk, Peter J. Van Veldhuizen, Michael...> ;Journal of Patient-Reported Outcomes. 2018 Jun 13
• 8 citations
  Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).
  Brea Lipe, Suman Kambhampati, Peter J. Van Veldhuizen, Abdulraheem Yacoub, Omar S. Aljitawi, Joseph R. Mikhael> ;Blood Cancer Journal. 2017 Dec 14
• The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.
  Haque, I.,Subramanian, A.,Huang, C. H.,Godwin, A. K.,Van Veldhuizen, P. J.,Banerjee, S.,Banerjee, S. K.> ;Int J Mol Sci. 2018 Jan 06
• 2 citations
  The Role of High Dose Interleukin-2 in the Era of Targeted Therapy
  Jessie Gills, William P. Parker, Scott C. Pate, Sida Niu, Peter J. Van Veldhuizen, Moben Mirza, Jeffery M. Holzbeierlein, Eugene Lee> ;The Journal of Urology. 2017 Sep 1
• 1 citations
  Metastatic prostate cancer in the modern era of PSA screening.
  Philip A. Fontenot, Avinash Nehra, William P. Parker, Hadley Wyre, Moben Mirza, David A. Duchene, Jeffrey M. Holzbeierlein, James Brantley Thrasher, Peter J. Van Veldh...> ;International Braz j Urol. 2017 May 1
• 14 citations
  Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma ...
  Rama Garimella, Priyanka Tadikonda, Ossama Tawfik, Sumedha Gunewardena, Peter S. N. Rowe, Peter J. Van Veldhuizen> ;International Journal of Molecular Sciences. 2017 Mar 16
• 25 citations
  Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
  Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
• 4 citations
  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
  Guru Sonpavde, Gregory R. Pond, Melissa Plets, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Celestia S. Higano, Nich...> ;Clinical Genitourinary Cancer. 2016 May 20
• 23 citations
  Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells
  Alok De, Benjamin Powers, Archana De, Jianping Zhou, Siddarth Sharma, Peter J. Van Veldhuizen, Ajay Bansal, Ramratan Sharma, Mukut Sharma> ;Oncotarget. 2016 Apr 25
• 8 citations
  Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.
  Chao H. Huang, Stephen K. Williamson, Prakash Neupane, Sarah A. Taylor, Ace Allen, Nora J. Smart, Adelina M. Uypeckcuat, Sarah Spencer, Jo Wick, Holly J. Smith, Peter ...> ;Frontiers in Oncology. 2016 Jan 13
• 4 citations
  Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy.
  Travis Williams, Robert R. Rodriguez, Katie S. Murray, Aaron Kovaleski, Rashna Madan, Peter J. Van Veldhuizen> ;Urology. 2015 Feb 1
• 20 citations
  A potential regulatory loop between Lin28B:miR‑212 in androgen-independent prostate cancer.
  Emma Borrego-Diaz, Benjamin C. Powers, Vugar Azizov, Scott Lovell, Ruben Reyes, Bradley Chapman, Ossama Tawfik, Douglas H. McGregor, Francisco J. Diaz, Xinkun Wang, Pe...> ;International Journal of Oncology. 2014 Dec 1
• 31 citations
  A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer
  Chao H. Huang, Jo Wick, Gurusingham Sitta Sittampalam, Victor Sanjit Nirmalanandhan, Apar Kishor Ganti, Prakash Neupane, Stephen K. Williamson, Andrew K. Godwin, Sarah...> ;Frontiers in Oncology. 2014 Oct 14
• 35 citations
  Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
  Amir Goldkorn, Benjamin Ely, Catherine M. Tangen, Yu-Chong Tai, Tong Xu, Hongli Li, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci...> ;International Journal of Cancer. 2015 Apr 15
• 15 citations
  Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in 11C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence
  Reginald W Dusing, Warner Peng, Sue-Min Lai, Gordon L. Grado, Jeffrey M. Holzbeierlein, J. Brantley Thrasher, Jacqueline Hill, Peter J. Van Veldhuizen> ;Clinical Nuclear Medicine. 2014 Sep 1
• Join now to see all

Journal Articles

• Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...  
  Goldkorn A, Ely B, Tangen CM, Tai Y, Xu T, Hongli Li, Twardowski P, Van Veldhuizen PJ, Neeraj Agarwal N, Carducci MA, Monk III JP, Garzotto M, Mack PC, Lara Jr. P, Hig..., Journal of Clinical Oncology, 1/10/2013
• Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy  
  Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators, Eur J Cancer, 1/1/2013
• Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer  
  Dubey S, Gunewardena S, Van Veldhuizen P, Thrasher JB, Karan D, Journal for Immunotherapy of Cancer, 1/1/2013
• Mycobacterium Bovis BCG Strain Osteomyelitis Masquerading as Spinal Metastasis from Bladder Cancer  
  Chuda R, Poddutoori P, Van Veldhuizen P, Kansas Journal of Medicine, 1/1/2012
• Cancer immunotherapy: a paradigm shift for prostate cancer treatment  
  Karan D, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Nat Rev Urol, 1/1/2012
• Prostate Cancer Immunotherapy: An Evolving Field  
  Hashmi M, Karan D, Phadke S, Saunthararajah Y, Kambhampati S, Van Veldhuizen P, Current Cancer Therapy Reviews, 1/1/2012
• Adenovirus-based Immunotherapy for Prostate Cancer  
  Dubey S, Van Veldhuizen P, Karan D, Current Cancer Therapy Reviews, 1/1/2012
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, place...  
  Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li J..., Lancet Oncol, 1/1/2012
• Abiraterone and increased survival in metastatic prostate cancer  
  de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Che..., N Engl J Med, 1/26/2011
• Imaging Studies that can be used for complimentary & alternative medicine clinical studies  
  Dusing RW, Drisko JA, Grado GG, Holzbeierlein JM, Van Veldhuizen P, Urology Clinics of North America, 1/1/2011
• S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5-Fluorouracil, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach  
  Blanke CD, Chansky K, Christman KL, Hundahl SA, Issel BF, Van Veldhuizen PJ, et al, Am Journal of Clinical Oncology, 1/1/2010
• Results of the Southwest Oncology Group phase II evaluation of ZD1839 for advanced transitional cell carcinoma of the urothelium  
  Petrylak DP, Tangen CM, Van Veldhuizen PJ, et al, 1/1/2010
• Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cellspericytes transition and recruitment through an interaction with NRP-1  
  Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK, Banerjee S., Mol Cancer, 1/1/2010
• 2-Methoxyestradiol inhibits barrett’s esophageal adenocarcinoma growth and differentiation through differential regulation of the betacatenin-E-caderin axis  
  Kambhampati S, Banerjee S, Dhar K, Mehta S, Haque I, Dhar G, Majumder M, Ray G, Van Veldhuizen PJ, Banerjee SK, Mol Cancer Ther, 1/1/2010
• Phase II Study of darinaparsin in patients with advanced hepatocellular carcinoma  
  Wu J, Henderson C, Feun L, Van Veldhuizen P, et al, Investigational New Drugs, 1/30/2009
• A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients with Advanced Renal Cell Cancer (RCC): Southwest Oncology Group Study 0312  
  Van Veldhuizen PJ, Hussey M, Primo NL Jr, Gumerlock PH, Clark J, Lange MK, Crawford DE, Am J Clin Oncol, 1/29/2009
• 2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2- methoxyestradiol-induced inhibition of cell growth  
  Van Veldhuizen PJ, Ray G, Banerjee S, Dhar G, Kambhampati S, Dhar A, Banerjee SK, Int J Cancer, 1/1/2009
• Gain of function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2  
  Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Van Veldhuizen PJ, Banerjee SK, Cancer Res, 1/1/2009
• Treatment Options for Unresectable Disease  
  Mirza M and Van Veldhuizen P, Federal Practitioner, 1/1/2009
• Managing Adverse Effects of Newer Therapies for Advanced Disease  
  Haideri N, Keefe S, Atherton C and Van Veldhuizen P, Federal Practitioner, 1/1/2009
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy  
  Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, et al, Journal of Urology, 1/1/2009
• Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer (AIPC) Previously Treated with Taxanes: Southwest Oncology Group Study  
  Beer TM, Goldman, B, Synold, Timothy W, Synold, Ryan CW, Lakshmi SV, Van Veldhuizen P, Dakhil S, Gandara DR, Drelichman A, Raghavan DR, Hussein M, Crawford DE, Clin Genitourin Cancer, 1/1/2008
• Effects of Soy Phytoestrogens on the Prostate  
  Goetz MA, Van Veldhuizen PJ, Thrasher JB, Prostate Cancer and Prostatic Diseases, 1/1/2007
• Dysgenetic Hypoplastic Kidney Simulating Lung Carcinoma  
  Huang C, McGregor D, Haltaufderhyde V, Victor F, Van Veldhuizen P, Lung Cancer, 1/1/2007
• The Validity of the Dissociative Disorders (Letter to the Editor)  
  Van Veldhuizen PJ, Comphrensive Psychiatry, 1/1/2007
• Join now to see all

Books/Book Chapters

• Current Cancer Therapy Reviews 
  Chapter: Prostate Cancer Immunotherapy 
  Karan D, Van Veldhuizen P2012
• Anti-Angiogenic and Medicinal Foods 
  Chapter: Angiogenic Switch: Roles of Estrogenic Compounds 
  Page 358 - 371Banerjee SK, Ray G, Van Veldhuizen P, Banerjee S2007
• Comprehensive Textbook of Genitourinary Oncology 
  Chapter: Seminoma: Management of Stage II Disease, Posttherapy residual masses and other special considerations 
  Smalley S, Van Veldhuizen PJ1998

Abstracts/Posters

• In vitro efficacy of MAGMAS inhibition in prostate cancer
  Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, ASCO; Genitourinary Cancers Symposium, 1/30/2014
• Applicability of MIC-1 as a potential biomarker for racial disparity in prostate cancer
  Dubey S, Wick J, Tawfik, O, Zainfeld D, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Karan D, AUA Annual Meeting, Orlando, FL, 1/16/2014
• MAGMAS inhibition in hepatocellular carcinoma
  Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, 248th ACS National Meeting, 1/10/2014
• SIRT1 as a potential therapeutic target in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Powers BC, Diaz F, Azizov V, Kasi Loknath Kumar A, Sharma M, Van Veldhuizen P, Translational Science, Omni Shoreham, Washington, DC, 1/1/2014
• Repurposing Drugs in Hepatocellular Carcinoma
  Powers BC, Bouzahzah B, Diaz F, Hunt S, Van Veldhuizen P, Borrego-Diaz Reyes E, Translational Science, Omni Shoreham, Washington, DC, 1/1/2014
• Applicability of MIC-1 as a potential biomarker for racial disparity in prostate cancer
  Zainfeld D, Dubey S, Wick Jo, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Karan D, SCS/AUA 92nd Annual Meeting, Chicago, IL, 1/18/2013
• Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer
  Dubey S, Gunewardena S, Van Veldhuizen P, Thrasher JB and Karan D, Society for Immunotherapy of Cancer; 28th Annual Meeting, 1/8/2013
• The effect of short-term soy isoflavone supplementation on gene transcripts and biochemical recurrence after curative treatment for localized prostate cancer
  Hamilton-Reeves J, Rubin JD, Camey SC, Godwin AK, Griffin JG, Chalise P, Van Veldhuizen P, AICR, 1/1/2013
• Effect of Denosumab on prolonging bone metastasis free survival (BMFS) in men with non metastatic castrate resistant prostate cancer (CRPC) presenting with aggressive ...
  Van Veldhuizen P, Smith MR, Saad F, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Damiao R, Marx G, Morote J, Zhishen Ye, Dansey R, Goessl C, AUA South Central Sectional, 1/24/2012
• Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive P...
  Saad F, Smith MR, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen P, Damiao R, Marx G, Morote J, Ye Z, Dansey R, Goessl CD, J Clin Oncol, 1/1/2012
• SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC)
  Quinn D, Tangen C, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Carducci A, Monk JP, Twardowski P, Van Veldhuizen P, Agarwal N, Higano CS, Vogelzang NJ, Thomps..., J Clin Oncol, 1/1/2012
• Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421)
  Goldkorn A, Ely B, Quinn D, Tangen C, Yu-Chong Tai, Twardowski P, Van Veldhuizen P, Agarwal N, Carducci A, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, ..., J Clin Oncol, 1/1/2012
• Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prost...
  Vogelzang NJ, Ely B, Louis M. Fink, Goldkorn A, Tangen C, Twardowski P, Van Veldhuizen P, Agarwal N, Carducci A, Monk JP, Ram H Datar, Garzotto M, Mack PC, Lara P, Hig..., J Clin Oncol, 1/1/2012
• Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutic...
  Sarantopoulos J, Hoering A, Synold TW, Mahalingam D, Wang D, Lenz HJ, O’Rourke P, Sexton R, Van Veldhuizen P, Mita M, Wong L, Mita AC, El-Khoueiry A, Chung VM, Gandar..., J Clin Oncol, 1/1/2012
• Docetaxel followed by temsirolimus in suppression of mTOR pathway
  Huang C, Van Veldhuizen P, Gadashova A, Williamson SK, Farassati F, J Clin Oncol, 1/1/2012
• Sequential docetaxel followed by mTOR inhibitor temsirolimus can suppress PI3K over-activation resistance mechanism
  Huang C, Van Veldhuizen P, Gadashova A, Williamson SK, Farassati F, Markers in Cancer Conference, 1/1/2012
• Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of G-CSF: a potential neoplastic marker?
  Kumar AKL, Holzbeierlein J, Van Veldhuizen P, National ACP Meeting, 1/1/2012
• Denosumab and bone metastasis-free survival in men with castrate-resistant prostate cancer: subgroup analyses from an international, double-blind, randomized, phase 3 ...
  Wong S, Smith M, Oudard S, Karsh L, Egerdie B, Van Veldhuizen P, Gomez-Veiga F, Dearnaley D, Fisher H, Wirth M, Charu V, Kuepper F, Montes de Oca L, Rendon R, Julka PK..., ISOPP Meeting, 1/1/2012
• Denosumab Delays Development of Multiple Bone Metastases in Men With Castration-Resistant Prostate Cancer
  Smith MR, Saad F, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen P, Damiao R, Marx G, Morote J, Feng A, Dansey R, Goessl C, AUA Meeting, 1/1/2012
• A QTc study of cabazitaxel in patients with advanced solid tumors
  Wade JL, Dakhil S, Baron A, Rottey S, Millard FE, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw P, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, TX..., J Clin Oncol, 1/1/2012
• MK-0646 (MK), insulin growth factor 1 receptor (IGF-1R) antibody combined with pemetrexed (P) and cisplatin (C) in stage IIIb or IV metastatic nonsquamous lung cancer ...
  Huang C, Kelly K, Williamson SK, Neupane P, Taylor SA, Allen A, Wick J, Van Veldhuizen P, J Clin Oncol, 1/1/2012
• Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive P...
  Smith MR, Saad F, Shore ND, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen PJ, Damião R, Marx GM, Morote J, Feng A, Dansey R, Dietrich Goessl C, J Clin Oncol; Genitourinary Cancers Symposium, 1/1/2012
• Lin28B as a master oncogene regulator in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Kambhampati S, Azizov V, Reyes R, Banerjee S, Haideri N, Power B, Wang X, Godwin A, Banerjee S and Van Veldhuizen P, MBRF meeting, 1/1/2012
• MicroRNA profiling in 2ME2 exposes Barrett’s esophageal cells
  Borrego-Diaz E, Azizov V, Banerjee S, Haque I, Power B, Wang X, Van Veldhuizen P, Banerjee S, Kambhampati S, MBRF meeting, 1/1/2012
• 2ME2 regulates microRNA expression throughout Lin28B pathway in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Kambhampati S, Azizov V, Banerjee S, Haque I, Haideri N, Power B, Wang X, Sand B, Van Veldhuizen P, MBRF meeting, 1/1/2012
• Join now to see all